A Randomized, Double-Blind, Placebo-Controlled, Ascending Single Dose Study of E6007 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 12 Sep 2014
At a glance
- Drugs E 6007 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions
- Sponsors Eisai Inc
- 31 Jan 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
- 31 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 20 Oct 2010 New trial record